Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance.
- NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_assertion description "[Dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor ([HER]-1/EGFR, HER-2, and HER-4) tyrosine kinase inhibitor, demonstrated antitumor activity in Western patients with non-small-cell lung cancer (NSCLC) at a dose of 45 mg once daily.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance.
- NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_assertion evidence source_evidence_literature NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance.
- NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_assertion SIO_000772 25521398 NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance.
- NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_assertion wasDerivedFrom befree-2016 NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance.
- NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_assertion wasGeneratedBy ECO_0000203 NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance.
- befree-2016 importedOn "2016-02-19" NP1249191.RA1Tf0o3zgvA_N4niJR5N8Dea9vVG-XGldReNhpF60tsE130_provenance.